ClinicalTrials.gg
RecruitingNCT06922383Updated Jun 29, 2026

A Clinical Study of Arfolitixorin in Patients With mCRC

A Phase 1/2 interventional study of Arfolitixorin and Leucovorin in Metastatic Colorectal Cancer (mCRC), sponsored by Isofol Medical AB. Recruiting at 3 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Isofol Medical AB · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 353 studies in Colorectal Neoplasms with a site in Germany — 63 open to participants now, 90 under way, 19 of them phase 3. Colorectal Neoplasms · Germany.

Planned enrollment
191st of 290
90 · median 169
Started
2025
with 24 others
Phase 1/2
39 of 353
12 open now
Primary completion
2028-11
later than 65 of 89 live
Registered
331st of 353
by date

Among the 353 studies in Colorectal Neoplasms with a site in Germany, this one is the 191st largest by planned enrollment of the 290 interventional ones that give a count, is one of 25 that started in 2025, is one of 39 in phase 1/2, reaches primary completion later than 65 of the 89 other live ones, and was the 331st registered.

Colorectal Neoplasms

6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

63 of the 353 studies in Colorectal Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 353 studies in Colorectal Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

This is a clinical research study taking place in Germany. Patients with colorectal cancer at a stage of the disease where metastases occur may take part in the study. A maximum of 90 people will participate in the study.

There is already a standard therapy for treatment of colorectal cancer. This therapy contains a combination of the medicines leucovorin, fluorouracil, oxaliplatin/irinotecan and bevacizumab/cetuximab/panitumumab.

The sponsoring company is developing the new therapy called arfolitixorin. In this study, patients with colorectal cancer will be given arfolitixorin instead of the standard treatment leucovorin. Different patients will receive treatment with different strengths (doses) of arfolitixorin. Treatment with fluorouracil, oxaliplatin/irinotecan and bevacizumab/cetuximab/panitumumab will also be administrated.

The researchers want to find out if arfolitixorin could have an advantage over the standard therapy with leucovorin. They also want to investigate which dose of arfolitixorin is the maximum tolerated dose and if arfolitixorin is safe to use.

The product being tested, arfolitixorin, like leucovorin, belongs to a group of substances called folates which are naturally occurring forms of a type of B vitamin. Folates are administered in combination with one or more chemotherapeutic agents to enhance their effect on cancer cells.

The main mechanism of action of arfolitixorin is the same as that of leucovorin when used together with fluorouracil. However, leucovorin must first be converted into the active form in the body, whereas arfolitixorin already is in the active form. Leucovorin does not work equally well in all patients. By bypassing the metabolic activation of arfolitixorin, it is assumed that arfolitixorin works in a larger number of patients and has a stronger and longer efficacy in cancer treatment together with fluorouracil.

However, the efficacy of arfolitixorin has not yet been proven, and the substance has not been approved for the treatment of colorectal cancer. To date, arfolitixorin has been tested by around 420 volunteers and patients with colorectal cancer in different clinical studies. These studies have shown that arfolitixorin is safe and potentially can be of clinical benefit in patients with colorectal cancer when used in combination with fluorouracil, oxaliplatin and bevacizumab.

In the largest clinical study completed so far, arfolitixorin was shown to be equally effective compared to standard therapy with leucovorin, but not more effective. Additional results from this study suggested that the dose of arfolitixorin given did not deliver a sufficiently high amount of active substance into the tumor. Therefore, higher doses of arfolitixorin will be tested in this study to possibly achieve a better clinical effect. Further analyses also indicated that high accuracy regarding the timing and duration of the administration of the different treatments is important to achieve better efficacy of arfolitixorin.

Based on the available data, and the risk and benefit assessments performed, the Sponsor deems that it is relevant to further investigate the safety and tolerability, as well as the efficacy of arfolitixorin when given in combination with fluorouracil, oxaliplatin/irinotecan and bevacizumab/cetuximab/panitumumab. The proposed study design is believed to address all the main previous findings with the purpose to increase the efficacy while maintaining an acceptable safety profile.

The study is divided into two parts. In the first part, up to five different doses of arfolitixorin will be investigated to find the maximum tolerated dose of arfolitixorin as well as the optimal duration time of administration.

The second part of the study will be based on the results from the first part. Two doses of arfolitixorin will be tested for safety, tolerability and anti-tumor effect. In the second part, participants will be randomly assigned to one of two dose groups or a control group (receiving the Standard of Care) using a computer program. This so-called randomization procedure is comparable to tossing a coin.

All patients that participate in the study will receive treatment every 2 weeks. The treatment will be given as an infusion into a vein. The number of treatment administrations that will be given is not predetermined but depends on the progression of the patient's disease.The treatment will continue every 2 weeks as long as the patient benefits from the treatment.

During the study period, the patient's disease and potential response to treatment, including shrinkage of the tumor and/or improvement of symptoms, will be monitored by imaging examinations, using so-called computer tomography (CT) or magnetic resonance imaging (MRI). The patient's state of health will also be monitored by physical examinations, and laboratory tests of urine and blood, as well as assessment of any side effects.

Read the detailed description

This is a Phase 1b/2 study to determine the safety and preliminary efficacy of arfolitixorin (replacing LV) as part of eligible 5-FU based backbone treatment regimens in patients with mCRC eligible for first-line therapy.

The study will include a Phase 1b dose-finding part followed by a randomized Phase 2 dose optimization part including an SoC arm.

Eligible patients will undergo baseline assessments (within 28 days prior to treatment initiation) and repeat imaging using computed tomography (CT) or magnetic resonance imaging (MRI) after 6 and 12 weeks, and every 12 weeks thereafter as long as on study treatment.

In Phase1b, patients will receive treatment with ARFOX + bevacizumab. In Phase 2, patients will receive treatment with arfolitixorin (replacing LV) as part of eligible 5-FU based backbone treatment (i.e., ARFOX + bevacizumab/cetuximab/panitumumab or ARFIRI + bevacizumab/cetuximab/panitumumab) or SoC (including LV) as part of eligible 5-FU based backbone treatment (i.e., FOLFOX + bevacizumab/cetuximab/panitumumab or FOLFIRI + bevacizumab/cetuximab/panitumumab).

All patients will receive treatment every 14 days (+7 days) until progressive disease (PD), or clear clinical deterioration according to the Investigator's judgment, and as long as the patient is tolerating the treatment and agrees to continue.

After completion of study treatment, patients will complete an EOT visit within 30 days of discontinuation, and all patients should be followed in line with the site's SoC scheme.

Subsequent study follow-up contacts/visits will be performed every 90 days (±15 days) after the EOT visit treatment, until 60% of the OS events have been collected or 24 months after last patient in (LPI), whichever comes first. The follow-up contacts may be conducted via telephone, via clinic visits, via local practitioner, via review of medical records or other means found suitable.

At the follow-up visits, information on any subsequent cancer treatments will be collected, recording and assessment of serious adverse events (SAEs) considered to be related to the study treatment will be performed, and survival status will be noted. All AEs collected during the reporting period still ongoing at the EOT visit will be followed until resolution or stabilization, or until deemed not necessary by the Investigator. All SAEs collected during the reporting period still ongoing at the EOT visit will be followed up until the patient has recovered, stabilized, or recovered with sequelae.

During the Phase 1b part of the study, a dose escalation design will be utilized to identify the MTD and the duration of administration of arfolitixorin to be used in combination with 5-FU, oxaliplatin and bevacizumab. A Safety Review Committee (SRC) will review AEs, SAEs, dose-limiting toxicities (DLTs) as defined in the Clinical Study Protocol, and PK data and make recommendations regarding which dose level and cohort size to be tested for the next cohort, as well as the MTD. The SRC may also make recommendations of the duration of the infusion if there are safety findings that potentially correlate to a non-acceptable maximum plasma (peak) drug concentration (Cmax).

The dose escalation schema will be based on a Bayesian optimal interval (BOIN) design where the decision of dose escalation or de-escalation involves a simple comparison of the observed DLT rate at the current dose with the prespecified dose escalation and de-escalation boundaries.

The Phase 2 part of the study will be a randomized study where patients will be allocated to 1 of 2 dose levels of arfolitixorin, or to treatment with SoC. The higher dose level of arfolitixorin will be the MTD as determined in Phase 1b, and the lower dose will be a dose level below the MTD in Phase 1b, as determined by the SRC. The SRC will also review safety and efficacy data on a regular basis during Phase 2.

03

Conditions studied

  • Metastatic Colorectal Cancer (mCRC)

Keywords

  • arfolitixorin
  • coloretal carcionoma
  • GI neoplasm
  • 5,10-MTHF
  • tetrahydrofolate
  • folate
  • leucovorin
  • cetuximab
  • bevacizumab
  • panitumumab
  • VEGF inhibitor
  • EGFR inhibitor
  • oxaliplatin
  • irinotecan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed ICF and ability to comply with protocol requirements.
  • Phase 1b: confirmed RAS mutant, MSS/pMMR, colorectal adenocarcinoma with disease, eligible for therapy with 5-FU, oxaliplatin, and bevacizumab regimen.

Phase 2:

Histologically confirmed, colorectal adenocarcinoma with metastatic disease, eligible for first-line therapy with 5-FU based backbones, i.e.:

  1. Patients with mutated RAS who are candidates for therapy with FOLFOX or FOLFIRI plus bevacizumab.
  2. Patients with WT RAS or WT BRAF and left-sided tumors who are candidates for therapy with FOLFOX or FOLFIRI plus cetuximab or panitumumab.

    • Tumor specimen (formalin-fixed, paraffin-embedded [FFPE]) available.
    • Acceptable hematologic laboratory values defined as:

a) ≥90 g/L. b) (ANC) ≥1.5 × 109/L. c) ≥100 × 109/L.

  • Adequate organ function as defined by the following laboratory values:

    1. Total serum ≤1.5 × (ULN).
    2. and AST ≤3 × ULN (≤5 × ULN in case of hepatic metastases).
    3. Creatinine ≤1.5 × ULN, or ≥50 mL/min (as measured according to Cockcroft-Gault equation).
  • Age ≥18 years at the time of signing the ICF.
  • Radiographically per (version 1.1) within 28 days of treatment allocation.
  • (ECOG) performance status of 0 or 1.
  • of >12 weeks.
  • Female patients must be surgically sterile, , or have negative results for a pregnancy test at screening, on a serum or urine sample obtained within 72 hours prior to initiation of study treatment.
  • Female patients of must agree to use highly effective measures while on study treatment and for at least 15 months (or longer if according to local labels) after study treatment discontinuation. Highly effective methods are those that achieve a failure rate of less than 1% per year when used consistently and correctly (as per the Clinical Trial Coordination Group [CTCG] Recommendations related to contraception and pregnancy testing in clinical trials, Version 1.2, 07 Mar 2024).
  • Female patients should agree to refrain from egg cell donation while on study treatment and for at least 15 months after the last dose of study treatment.
  • Male patients with female partners of childbearing potential must agree to use adequate contraceptive measures while on study treatment and for at least 12 months (or longer if according to local labels) after study treatment discontinuation.
  • Male patients should agree to refrain from sperm donation while on study treatment and for at least 12 months after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Indication for any mCRC surgery or anti-cancer treatment other than study treatment, including but not limited to resection as confirmed by a MTB.
  • Concomitant or previous malignancies with less than a 2-year disease free interval at the time of signing consent. Patients with adequately treated basal or squamous cell carcinoma of the skin, or adequately treated carcinoma in situ (e.g., cervix) may enroll irrespective of the time of diagnosis. Patients with controlled, advanced prostate cancer are permitted. Ongoing antihormonal therapy after breast or prostate cancer is permitted.
  • Prior 5-FU, oxaliplatin, irinotecan, bevacizumab, cetuximab, or panitumumab administration for mCRC.
  • More than 6 cycles (3 months) of oxaliplatin exposure during adjuvant treatment.
  • Known history of central nervous system (CNS) or carcinomatous meningitis.
  • Receipt of any product within 14 days or 5 half-lives prior to study treatment initiation, whichever is shortest. Note that participation in any other clinical study is not allowed as long as the patient is on study treatment.
  • Prior exposure to arfolitixorin.
  • Major surgery, or significant traumatic injury within 8 weeks of study treatment initiation.
  • to arfolitixorin, 5-FU, oxaliplatin or other platinum agent, irinotecan, bevacizumab, cetuximab or panitumumab, or to their .
  • Dihydropyrimidine dehydrogenase (DPD) enzyme deficiency test with a Clinical Pharmacogenetics Implementation Consortium (CPIC) activity score \<1.
  • Current evidence of any condition that could lead to higher risk or otherwise make participating in this study not in the best interest of the patient, including, but not limited to:

    1. Myocardial infarction or unstable angina within the past 6 months.
    2. Other structural heart disease (e.g., myocarditis, ventricular hypertrophy).
    3. (NYHA) functional classification Class II or greater.
    4. syndrome >450 ms.
    5. Slow or irregular ventricular rates; other serious arrhythmias requiring medication for treatment.
    6. (LVEF) \<55%.
    7. Active infection requiring i.v. antibiotics.
    8. Ongoing drug or alcohol abuse.
    9. Inadequately controlled hypertension (defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 mmHg). Initiation of antihypertensives is permitted provided adequate control is documented over at least 1 week before starting treatment.
  • Sensory peripheral neuropathy Grade ≥2.
  • Pregnancy or lactation.
  • Any medical condition, or ongoing treatment with drugs, which in the opinion of the Investigator, places the patient at an unacceptably high risk for toxicities, or any psychological, familial, sociological or geographical condition that potentially hampers compliance with the study protocol and follow-up schedule.
  • BRAF-mutant or deficient in mismatch repair (dMMR)/microsatellite instability-high (MSI-H) mCRC.
  • Eligibility for treatment with FOLFIRINOX regimens.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    High dose level

    The higher dose level of arfolitixorin in Phase 2 will be the maximum tolerated dose as determined in Phase 1b. The arfolitixorin will be given as i.v. infusion. Patients in this study will receive the IMP arfolitixorin as part of eligible 5-FU based backbone treatment (i.e., ARFOX + bevacizumab/cetuximab/panitumumab or ARFIRI + bevacizumab/cetuximab/panitumumab). The duration of the infusion will be determined in Phase 1b.

    Drug: Arfolitixorin

  • Experimental
    Low dose level

    The lower dose level of arfolitixorin in Phase 2 will be a dose level below the maximum tolerated dose in Phase 1b, as determined by the SRC. The arfolitixorin will be given as i.v. infusion. Patients in this study will receive the IMP arfolitixorin as part of eligible 5-FU based backbone treatment (i.e., ARFOX + bevacizumab/cetuximab/panitumumab or ARFIRI + bevacizumab/cetuximab/panitumumab). The duration of the infusion will be determined in Phase 1b.

    Drug: Arfolitixorin

  • Active comparator
    Standard of Care (leucovorin/levoleucovorin)

    Patients in the SoC group will receive treatment with leucovorin (LV) as part of eligible 5-FU based backbone treatment (i.e., FOLFOX + bevacizumab/cetuximab/panitumumab or FOLFIRI + bevacizumab/cetuximab/panitumumab). LV will be administered as a 400 mg/m2 (for leucovorin) i.v. infusion as per the standard of care procedure at the study site and the specific label. (Note that other doses may be applicable as per the label, if e.g. levoleucovorin is given).

    Other: Leucovorin

Interventions

  • Every 14 days during treatment phase, antibody treatment (bevacizumab 5 mg/kg or cetuximab 500 mg/m² or panitumumab 6 mg/kg) will be administered as an i.v. infusion, followed by oxaliplatin 85 mg/m² or irinotecan 180 mg/m² administered as an i.v. infusion, and arfolitixorin administred as an i.v. infusion, followed by 5-FU administered as a 400 mg/m² i.v. bolus + a 2400 mg/m² i.v. infusion.

  • OtherLeucovorin

    Patients in the SoC group will receive treatment with leucovorin as part of eligible 5-FU based backbone treatment. Every 14 days during treatment phase, antibody treatment (bevacizumab 5 mg/kg or cetuximab 500 mg/m² or panitumumab 6 mg/kg) will be administered as an i.v. infusion, followed by oxaliplatin 85 mg/m² or irinotecan 180 mg/m² administered as an i.v. infusion, and leucovorin 400 mg/m2 administered as an i.v. infusion, followed by 5-FU administered as a 400 mg/m² i.v. bolus + a 2400 mg/m² i.v. infusion.

06

What researchers measure

Primary outcomes

  1. Phase 1b: Number and severity of AEs and clinically significant abnormal laboratory findings

    Number and severity of AEs and clinically significant abnormal laboratory findings, regardless of causal relationship to ARFOX + bevacizumab will be measured to evaluate the safety and tolerability of ARFOX + bevacizumab in patients with mCRC. The outcome of Phase 1b is to determine the MTD of arfolitixorin (ARFOX + bevacizumab).

    Time frame: From enrollment until end of study, i.e. until death, an average of 24 months.

  2. Phase 2: Number and severity of AEs, including clinically significant abnormal laboratory findings, after 2 pre-defined dose levels of arfolitixorin

    Number and severity of AEs and clinically significant abnormal laboratory findings, regardless of causal relationship to any given treatment will be measured to evaluate the safety and tolerability of two pre-defined doses of arfolitixorin, in patients with mCRC, with SoC used as an internal control. The dose levels of arfolitixorin will be MTD and a dose level below MTD.

    Time frame: From enrollment until end of study, i.e. until death, an average of 24 months.

  3. Phase 2: Early signals of the anti-tumor activity of two pre-defined dose levels of arfolitixorin with SoC used as an internal control, in terms of ORR.

    ORR will be determined by assessing early signals of the anti-tumor activity of two pre-defined dose levels of arfolitixorin (MTD and a dose level below MTD). ORR is defined as the proportion of patients who have best overall response (BOR) of complete response (CR), or partial response (PR), measured from the start of the study treatment until the end of treatment (EOT) by the Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1).

    Time frame: From enrollment until end of treatment, i.e. until progressive disease, or clear clinical deterioration according to the Investigator's judgment, and as long as the patient is tolerating the treatment and agrees to continue, an average of 11 months.

  4. Phase 2: Early signals of the anti-tumor activity of two pre-defined dose levels of arfolitixorin with SoC used as an internal control, in terms of duration of response (DOR).

    Duration of response (DOR) will be determined by assessing early signals of the anti-tumor activity of two pre-defined dose levels of arfolitixorin (MTD and a dose level below MTD). DOR is defined as the duration of CR or PR.

    Time frame: From enrollment until end of treatment, i.e. until progressive disease, or clear clinical deterioration according to the Investigator's judgment, and as long as the patient is tolerating the treatment and agrees to continue, an average of 11 months.

Secondary outcomes

  1. Phase 1b: Anti-tumor activity of ARFOX + bevacizumab in terms of ORR

    Anti-tumor activity of ARFOX + bevacizumab will be assessed in patients with mCRC in terms of ORR, defined as the proportion of patients who have BOR of CR, or PR, measured by RECIST (version 1.1).

    Time frame: From enrollment until end of treatment, i.e. until progressive disease, or clear clinical deterioration according to the Investigator's judgment, and as long as the patient is tolerating the treatment and agrees to continue, an average of 11 months.

  2. Phase 1b: Anti-tumor activity of ARFOX + bevacizumab in terms of PFS.

    Anti-tumor activity of ARFOX + bevacizumab will be assessed in patients with mCRC in terms of PFS, defined as the time from the first study dose date to the date of first documentation of disease progression or death (whichever occurs first).

    Time frame: From the first study dose date to the date of first documentation of disease progression or death (whichever occurs first), an average 11 months.

  3. Phase 1b: Anti-tumor activity of ARFOX + bevacizumab in terms of OS.

    Anti-tumor activity of ARFOX + bevacizumab will be assessed in patients with mCRC in terms of OS, measured from the date of study treatment initiation to the date of death.

    Time frame: From enrollment until end of study, i.e. until death, an average of 24 months.

  4. Phase 1b: Plasma concentration of arfolitixorin

    Plasma concentration of arfolitixorin will be measured to determine the PK profile of arfolitixorin, administered in combination with bevacizumab, oxaliplatin and 5-FU.

    Time frame: Assessed just before the end of the infusion of arfolitixorin, and at 5, 10, 20, and 60 minutes after finished infusion of arfolitixorin, on day 1 and day 15.

  5. Phase 2: Anti-tumor activity of 2 pre-defined dose levels of arfolitixorin, in terms of OS.

    Anti-tumor activity of 2 pre-defined dose levels of arfolitixorin (MTD and a dose level below MTD) with SoC used as an internal control, in patients with mCRC will be assessed in terms of OS. OS (efficacy endpoint), measured from the date of study treatment initiation to the date of death.

    Time frame: From enrollment until end of study, i.e. until death, an average of 24 months.

  6. Phase 2: Anti-tumor activity of 2 pre-defined dose levels of arfolitixorin, in terms of PFS.

    Anti-tumor activity of 2 pre-defined dose levels of arfolitixorin (MTD and a dose level below MTD) with SoC used as an internal control, in patients with mCRC will be assessed in terms of PFS, defined as the time from the date of the first study dose to the date of first documentation of disease progression or death (whichever occurs first).

    Time frame: From the first study dose date to the date of first documentation of disease progression or death (whichever occurs first), an average 11 months.

  7. Phase 2: Anti-tumor activity of 2 pre-defined dose levels of arfolitixorin, in terms of time to response (TTR).

    Anti-tumor activity of 2 pre-defined dose levels of arfolitixorin (MTD and a dose level below MTD) with SoC used as an internal control, in patients with mCRC will be assessed in terms of time to response (TTR). TTR, defined as the time from the first study dose date to the date of first documentation of CR or PR measured by RECIST (version 1.1).

    Time frame: Measured from the start of the study treatment until the EOT visit, an average of 11 months.

  8. Phase 2: Anti-tumor activity of 2 pre-defined dose levels of arfolitixorin, in terms of disease control rate (DCR).

    Anti-tumor activity of 2 pre-defined dose levels of arfolitixorin (MTD and a dose level below MTD) with SoC used as an internal control, in patients with mCRC will be assessed in terms of disease control rate (DCR). DCR, defined as the proportion of patients who have BOR of CR, PR, or SD ≥8 weeks.

    Time frame: Measured from the start of the study treatment until the EOT visit, an average of 11 months.

  9. Phase 2: Anti-tumor activity of 2 pre-defined dose levels of arfolitixorin, in terms of depth of response (DpR).

    Anti-tumor activity of 2 pre-defined dose levels of arfolitixorin (MTD and a dose level below MTD) with SoC used as an internal control, in patients with mCRC will be assessed in terms of depth of response (DpR). DpR, defined as the maximum percentage change in tumor size compared with baseline.

    Time frame: Measured from the start of the study treatment until the EOT visit, an average of 11 months.

  10. Phase 2: OS as a safety outcome

    OS will be assessed as a safety outcome for 2 pre-defined dose levels of arfolitixorin (MTD and a dose level below MTD) with SoC used as an internal control, in patients with mCRC.

    Time frame: OS (safety [harm] endpoint), measured from the date of study treatment initiation to the date of death, 24 months.

  11. Phase 2: Proportion of patients qualifying for curative metastasis resection after treatment with study drug

    The effect of 2 pre-defined dose levels of arfolitixorin (MTD and a dose level below MTD) with SoC used as an internal control, in patients with mCRC, will be assessed by measuring the proportion of patients qualifying for curative metastasis resection.

    Time frame: Measured from the start of the study treatment until the EOT visit, an average of 11 months.

07

Study locations

1 of 3 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Nov 2028, 43 months after the start.

Of 158 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 82. This study's planned 43 months is below that.

Counting every sponsor, half of 260 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2025
First posted
Apr 10, 2025
StartActual
Apr 10, 2025
Primary completionEst.
Nov 30, 2028
CompletionEst.
Dec 31, 2029
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06922383
Lead sponsor
Isofol Medical AB
Responsible party
Sponsor
First posted
Apr 10, 2025
Start date
Apr 10, 2025
Primary completion
Nov 30, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Jun 29, 2026

Study contacts

Roger Tell, MD, PhD
Contact
roger.tell@isofolmedical.com
+46760293911
Sebastian Stintzing, Prof. Dr. MD
principal investigator · Charité - Universitaetsmedizin Berlin, Berlin, 10117

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: L-(+)-methylenetetrahydrofolic acid

Start the discussion